UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Transcription

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washingtn, D.C FORM 8-K CURRENT REPORT Pursuant t Sectin 13 r 15(d) f the Securities Exchange Act f 1934 Date f Reprt (Date f earliest event reprted): February 22, 2019 Diplmat Pharmacy, Inc. (Exact Name f Registrant as Specified in its Charter) Michigan (State r Other Jurisdictin f Incrpratin) (Cmmissin File Number) 4100 S. Saginaw St. Flint, Michigan (Address f Principal Executive Offices) (Zip Cde) (888) (Registrant s Telephne Number, Including Area Cde) (IRS Emplyer Identificatin N.) Check the apprpriate bx belw if the Frm 8-K filing is intended t simultaneusly satisfy the filing bligatin f the registrant under any f the fllwing prvisins ( seegeneral Instructin A.2. belw): Written cmmunicatins pursuant t Rule 425 under the Securities Act (17 CFR ) Sliciting material pursuant t Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-cmmencement cmmunicatins pursuant t Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-cmmencement cmmunicatins pursuant t Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c)) Indicate by check mark whether the registrant is an emerging grwth cmpany as defined in Rule 405 f the Securities Act f 1933 ( f this chapter) r Rule 12b-2 f the Securities Exchange Act f 1934 ( b-2 f this chapter). Emerging grwth cmpany If an emerging grwth cmpany, indicate by check mark if the registrant has elected nt t use the extended transitin perid fr cmplying with any new r revised financial accunting standards prvided pursuant t Sectin 13(a) f the Exchange Act.

2 Item 5.02 Departure f Directrs r Certain Officers; Electin f Directrs; Appintment f Certain Officers; Cmpensatry Arrangements f Certain Officers. On February 22, 2019, Jeff Park prvided the Bard f Directrs ( the Bard ) f Diplmat Pharmacy, Inc. (the Cmpany ) with ntice f his resignatin frm the Bard, effective immediately. A cpy f the Cmpany s news release regarding the freging matter is attached heret as Exhibit 99.1 and is incrprated herein by reference. Item 9.01 (d) Exhibits Financial Statements and Exhibits. Exhibit N. Descriptin 99.1 Cmpany news release dated February 28,

3 SIGNATURE Pursuant t the requirements f the Securities Exchange Act f 1934, as amended, the Registrant has duly caused this reprt t be signed n its behalf by the undersigned hereunt duly authrized. Diplmat Pharmacy, Inc. By: /s/ Brian T. Griffin Brian T. Griffin Chief Executive Officer Date: February 28,

4 Exhibit 99.1 FOR IMM EDIATE RELEASE: Feb. 28, 2019 CONTACT: Terri Anne Pwers, Vice President f Investr Relatins tpwers@diplmat.is Elizabeth Carr, Crprate Cmmunicatins Manager press@diplmat.is Diplmat Annunces Resignatin f Jeff Park frm Bard f Directrs FLINT, Mich. Feb. 28, 2019 Diplmat Pharmacy, Inc. (NYSE: DPLO), annunced tday that the Cmpany s bard f directrs accepted the resignatin f directr Jeff Park, effective Feb. 22, Mr. Park has been a member f Diplmat s bard f directrs since June He served as interim CEO f Diplmat frm January t May The Nminating and Crprate Gvernance Cmmittee f the bard f directrs expects t make a recmmendatin t the full bard in the near future t fill the vacant directr psitin. T learn mre abut Diplmat, visit diplmat.is. Frward-Lking Statements This press release cntains frward-lking statements made pursuant t the safe harbr prvisins f the Private Securities Litigatin Refrm Act f Frward-lking statements give current expectatins r frecasts f future events r ur future financial r perating perfrmance and include Diplmat s expectatins regarding the directr search prcess and filling the vacancy n the bard f directrs. The frward-lking statements cntained in this press release are based n management s gd-faith belief and reasnable judgment based n current infrmatin. These statements are qualified by imprtant risks and uncertainties, many f which are beynd ur cntrl, that culd cause ur actual results t differ materially frm thse frecasted r indicated by such frwardlking statements. These risks and uncertainties include: the risk that the directr search prcess and filling f the vacancy n the bard f directrs is nt cmpleted in a timely manner and/r that a satisfactry directr is nt identified; the directr selected culd be negatively viewed by investrs and subsequently impact the perceptin f Diplmat and/r its bard f directrs and the value f ur cmmn stck; and the additinal factrs set frth in Risk Factrs in Diplmat s mst recent Annual Reprt n Frm 10-K and in subsequent reprts filed with r furnished t the Securities and Exchange Cmmissin. Except as may be required by any applicable laws, Diplmat assumes n

5 bligatin t publicly update such frward-lking statements, which are made as f the date heref r the earlier date specified herein, whether as a result f new infrmatin, future develpments, r therwise. Abut Diplmat Diplmat (NYSE: DPLO) is the natin s largest independent prvider f specialty pharmacy and infusin services. Diplmat helps peple with cmplex and chrnic health cnditins in all 50 states, partnering with payers, prviders, hspitals, manufacturers, and mre. Rted in this patient care expertise, Diplmat als serves payers thrugh CastiaRx, a leading specialty benefit manager, and ffers tailred slutins fr healthcare innvatrs thrugh EnvyHealth. Diplmat pened its drs in 1975 as a neighbrhd pharmacy with ne essential tenet: Take gd care f patients and the rest falls int place. Tday, that traditin cntinues always fcused n imprving patient care. Fr mre infrmatin, visit diplmat.is. ###